Public Employees Retirement System of Ohio purchased a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 127,162 shares of the company’s stock, valued at approximately $9,138,000.
A number of other institutional investors have also modified their holdings of ZTS. Ancora Advisors LLC acquired a new position in shares of Zoetis in the 2nd quarter valued at about $2,642,000. Jones Financial Companies Lllp purchased a new position in Zoetis during the second quarter valued at approximately $1,877,000. Cullen Capital Management LLC acquired a new position in Zoetis in the second quarter valued at approximately $801,000. Dearborn Partners LLC purchased a new stake in Zoetis in the 2nd quarter worth approximately $12,639,000. Finally, Ally Financial Inc. purchased a new stake in Zoetis in the 2nd quarter worth approximately $790,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Zoetis Trading Down 0.5%
Shares of Zoetis stock opened at $76.99 on Tuesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock’s 50 day simple moving average is $75.59 and its 200-day simple moving average is $95.04. The stock has a market cap of $31.81 billion, a P/E ratio of 12.68, a P/E/G ratio of 1.80 and a beta of 0.73. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49.
Analyst Upgrades and Downgrades
ZTS has been the subject of several recent research reports. Citigroup cut their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Finally, Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $107.43.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
See Also
- Five stocks we like better than Zoetis
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
